デフォルト表紙
市場調査レポート
商品コード
348292

バイオプリザベーションの世界市場

Biopreservation

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 322 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.87円
バイオプリザベーションの世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 322 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のバイオプリザベーション市場について調査分析を行い、製品セグメント別(装置、媒体)、用途別(R&D、治療、その他)、生物検体別(臓器、幹細胞、組織、その他)に考察するとともに、米国、カナダ、日本、欧州、アジア太平洋地域、ラテンアメリカ、世界のその他の諸国の各市場について包括的に分析し、2013年~2020年の見通し、主要企業などについてまとめています。

第1章 イントロダクション、調査方法、製品の定義

第2章 エグゼクティブサマリー

  • 産業の概要
    • バイオプリザベーション:ヒューマンヘルスケアの向上に重要な活動
    • 急成長するバイオレポジトリーが市場成長の見通しを明るいものにしている
    • 競合シナリオ
  • 主な成長促進因子、市場動向
  • 製品の概要
    • バイオプリザベーション装置
    • バイオプリザベーション媒体
    • 生物検体の種類
    • バイオプリザベーション装置とメディアの用途
      • 治療
      • 研究
      • その他
  • 製品の導入
  • 最近の産業活動
  • 主要企業
  • 世界市場の概要

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • オランダ
    • その他の欧州諸国
  • アジア太平洋地域
    • 中国
    • インド
    • アジア太平洋地域のその他の諸国
  • ラテンアメリカ
    • ブラジル
    • ラテンアメリカのその他の諸国
  • 世界のその他の諸国
目次
Product Code: MCP-7986

Abstract:

Global Biopreservation Market to Reach $15.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Biopreservation estimated at US$5.5 Billion in the year 2020, is projected to reach a revised size of US$15.8 Billion by 2027, growing at a CAGR of 16.2% over the analysis period 2020-2027. Equipment, one of the segments analyzed in the report, is projected to record a 16% CAGR and reach US$11.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the LIMS segment is readjusted to a revised 15% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 21.1% CAGR

The Biopreservation market in the U.S. is estimated at US$1.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.7 Billion by the year 2027 trailing a CAGR of 20.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.5% and 14.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.

Media Segment to Record 17.2% CAGR

In the global Media segment, USA, Canada, Japan, China and Europe will drive the 16.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$834.2 Million in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.4 Billion by the year 2027, while Latin America will expand at a 18.7% CAGR through the analysis period.

Select Competitors (Total 82 Featured) -

  • Atlanta Biologicals, Inc.
  • BioCision, LLC
  • BioGenix, LLC
  • BioLife Solutions, Inc.
  • Biomatrica, Inc.
  • LabVantage Solutions, Inc.
  • Panasonic Corporation
  • Qiagen, Inc.
  • Thermo Fisher Scientific, Inc.
  • VWR International LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Biopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Biopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for LIMS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for LIMS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Media by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Media by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 11: World Current & Future Analysis for Bio-banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Bio-banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 15: World Current & Future Analysis for CD34+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 16: World 7-Year Perspective for CD34+ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 17: World Current & Future Analysis for CD19+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 18: World 7-Year Perspective for CD19+ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 19: World Current & Future Analysis for MSC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World 7-Year Perspective for MSC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 21: World Current & Future Analysis for iPSC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 22: World 7-Year Perspective for iPSC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 23: World Current & Future Analysis for hESC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 24: World 7-Year Perspective for hESC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World 7-Year Perspective for Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 27: World Current & Future Analysis for Other Cell Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 28: World 7-Year Perspective for Other Cell Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 29: USA Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 30: USA 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 33: USA Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 34: USA 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • CANADA
    • TABLE 35: Canada Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 36: Canada 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 39: Canada Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Canada 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • JAPAN
    • TABLE 41: Japan Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Japan 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 43: Japan Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 45: Japan Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Japan 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • CHINA
    • TABLE 47: China Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 48: China 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 49: China Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: China 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 51: China Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 52: China 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • EUROPE
    • TABLE 53: Europe Current & Future Analysis for Biopreservation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 54: Europe 7-Year Perspective for Biopreservation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 57: Europe Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 58: Europe 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 59: Europe Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Europe 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • FRANCE
    • TABLE 61: France Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 63: France Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 64: France 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 65: France Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 66: France 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • GERMANY
    • TABLE 67: Germany Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 69: Germany Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 70: Germany 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 71: Germany Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 72: Germany 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • ITALY
    • TABLE 73: Italy Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 75: Italy Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 76: Italy 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 77: Italy Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 78: Italy 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 79: UK Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 81: UK Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 82: UK 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 83: UK Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 84: UK 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • SPAIN
    • TABLE 85: Spain Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Spain 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 87: Spain Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 88: Spain 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 89: Spain Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 90: Spain 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • RUSSIA
    • TABLE 91: Russia Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Russia 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 93: Russia Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 94: Russia 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 95: Russia Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 96: Russia 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 97: Rest of Europe Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Europe 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 99: Rest of Europe Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 100: Rest of Europe 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 101: Rest of Europe Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 102: Rest of Europe 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 103: Asia-Pacific Current & Future Analysis for Biopreservation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific 7-Year Perspective for Biopreservation by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020 & 2027
    • TABLE 105: Asia-Pacific Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 106: Asia-Pacific 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 107: Asia-Pacific Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 108: Asia-Pacific 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 109: Asia-Pacific Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • AUSTRALIA
    • TABLE 111: Australia Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 112: Australia 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 113: Australia Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 114: Australia 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 115: Australia Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Australia 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • INDIA
    • TABLE 117: India Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 118: India 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 119: India Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 120: India 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 121: India Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: India 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • SOUTH KOREA
    • TABLE 123: South Korea Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 124: South Korea 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 125: South Korea Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 126: South Korea 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 127: South Korea Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: South Korea 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 129: Rest of Asia-Pacific Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 131: Rest of Asia-Pacific Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 132: Rest of Asia-Pacific 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 133: Rest of Asia-Pacific Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Asia-Pacific 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • LATIN AMERICA
    • TABLE 135: Latin America Current & Future Analysis for Biopreservation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 136: Latin America 7-Year Perspective for Biopreservation by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020 & 2027
    • TABLE 137: Latin America Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 138: Latin America 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Latin America 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 141: Latin America Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 142: Latin America 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • ARGENTINA
    • TABLE 143: Argentina Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 144: Argentina 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 145: Argentina Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Argentina 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 147: Argentina Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 148: Argentina 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • BRAZIL
    • TABLE 149: Brazil Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 150: Brazil 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 151: Brazil Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Brazil 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 153: Brazil Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 154: Brazil 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • MEXICO
    • TABLE 155: Mexico Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 156: Mexico 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 157: Mexico Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Mexico 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 159: Mexico Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 160: Mexico 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 162: Rest of Latin America 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 163: Rest of Latin America Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Latin America 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 165: Rest of Latin America Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 166: Rest of Latin America 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • MIDDLE EAST
    • TABLE 167: Middle East Current & Future Analysis for Biopreservation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 168: Middle East 7-Year Perspective for Biopreservation by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020 & 2027
    • TABLE 169: Middle East Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Middle East 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 171: Middle East Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 172: Middle East 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 173: Middle East Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 174: Middle East 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • IRAN
    • TABLE 175: Iran Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Iran 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 177: Iran Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 178: Iran 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 179: Iran Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 180: Iran 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • ISRAEL
    • TABLE 181: Israel Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Israel 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 183: Israel Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 184: Israel 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 185: Israel Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 186: Israel 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • SAUDI ARABIA
    • TABLE 187: Saudi Arabia Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Saudi Arabia 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 189: Saudi Arabia Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 190: Saudi Arabia 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 191: Saudi Arabia Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 192: Saudi Arabia 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 193: UAE Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: UAE 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 195: UAE Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 196: UAE 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 197: UAE Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 198: UAE 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 199: Rest of Middle East Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of Middle East 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 201: Rest of Middle East Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 202: Rest of Middle East 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 203: Rest of Middle East Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 204: Rest of Middle East 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027
  • AFRICA
    • TABLE 205: Africa Current & Future Analysis for Biopreservation by Product Type - Equipment, LIMS and Media - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Africa 7-Year Perspective for Biopreservation by Product Type - Percentage Breakdown of Value Sales for Equipment, LIMS and Media for the Years 2020 & 2027
    • TABLE 207: Africa Current & Future Analysis for Biopreservation by Application - Regenerative Medicine, Bio-banking and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 208: Africa 7-Year Perspective for Biopreservation by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Bio-banking and Drug Discovery for the Years 2020 & 2027
    • TABLE 209: Africa Current & Future Analysis for Biopreservation by Cell Provider - CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 210: Africa 7-Year Perspective for Biopreservation by Cell Provider - Percentage Breakdown of Value Sales for CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells and Other Cell Providers for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 82